May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Indications for Photodynamic Therapy (PDT) outside the TAP and VIP Trial
Author Affiliations & Notes
  • M. Schellenbeck
    Department of Ophthalmology, University Hospital Charité Campus Virchow, Berlin, Germany
  • V. Müller
    Department of Ophthalmology, University Hospital Charité Campus Virchow, Berlin, Germany
  • S. Lechner
    Department of Ophthalmology, University Hospital Charité Campus Virchow, Berlin, Germany
  • C. Hartmann
    Department of Ophthalmology, University Hospital Charité Campus Virchow, Berlin, Germany
  • Footnotes
    Commercial Relationships  M. Schellenbeck, None; V. Müller, None; S. Lechner, None; C. Hartmann, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3151. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Schellenbeck, V. Müller, S. Lechner, C. Hartmann; Indications for Photodynamic Therapy (PDT) outside the TAP and VIP Trial . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3151.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the safety and the long–term effect on visual acuity of photodynamic therapy (PDT) with verteporfin in the treatment of patients with choroidal neovascularisation (CNV) not secondary to age–related macular degeneration. Methods: Within the last 3 years a total of 47 patients with CNV secondary to pathologic myopia, inflammatory conditions such as multifocal choroiditis and presumed ocular histoplasmosis syndrome (POHS), central serous chorioretinopathy (CSC), autosomal dominat drusen, traumatic CNV and idiopathic causes have been treated with standard PDT and verteporfin. Results: The mean follow–up time is 15.7 months. The mean age of the patients is 37.6 years. A mean of 2.3 treatments (1–5) was performed. 41 out of 47 patients (87.2%) have been stabilized in visual acuity and lost less than 3 lines of visual acuity. 22 patients (46.8%) have improved in visual acuity (1 or more lines) and 14 patients had moderate vision loss of at least 3 lines. No clinically relevant side effects or complications were observed. Conclusions: PDT is a safe and effective treatment option for CNV not related to age–related macular degeneration. A majority of patients remained stable in visual acuity after PDT. Still the treatment of choroidal neovascularisation remains a challenging problem in opththalmology.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • photodynamic therapy • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×